Iovance Biotherapeutics (IOVA) is considered a strong buy, as indicated by the consensus rating and price target set by analysts.
- Consensus Rating: The consensus rating for IOVA is a "Strong Buy" based on the analysis of 11 analysts giving stock ratings to Iovance Biotherapeutics in the past 3 months.
- Average Price Target: The average price target for IOVA is $26.83, with a high forecast of $36.00 and a low forecast of $19.00. This represents a significant upside from the current price, with an average price target indicating a potential gain of 22.22% from the last closing price.
- Analyst Confidence: The strong buy rating and high price target suggest that analysts are confident in the company's future performance, which could be driven by the company's innovative pipeline, strategic partnerships, and potential regulatory approvals.
Given these points, it is clear that Iovance Biotherapeutics is considered a strong buy based on analyst ratings and price targets.
9/1/2024 11:33am
